Companies Cryptocurrencies
Trevi Therapeutics Inc
Trevi Therapeutics Inc
Exchange: NasdaqGM
IPO Date: 07/05/2019
CEO: Ms. Jennifer Good
Biotechnology Healthcare đź”—
  • TRVI
  • 2.235
  • 86462312
    market cap
  • 0.01499987
If you bought

shares of Trevi Therapeutics Inc (TRVI) on
You would have made
Old Price $12 Current Price $12

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 16 full-time employees. The firm is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson’s disease. The firm is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The firm has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.

Address: 195 Church St Fl 14 New Haven CONNECTICUT 06510

Stay updated.